STOCK TITAN
  1. Home
  2. News
  3. VINC

Vincerx Pharma Inc - VINC STOCK NEWS

Welcome to our dedicated news page for Vincerx Pharma (Ticker: VINC), a resource for investors and traders seeking the latest updates and insights on Vincerx Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vincerx Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vincerx Pharma's position in the market.

News
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 
Rhea-AI Summary
Vincerx Pharma presents positive preliminary Phase 1 data for VIP236 and VIP943 at AACR Annual Meeting 2024, highlighting the potential of their VersAptx platform to advance cancer therapies. VIP236 shows promising clinical activity with tumor reductions, while VIP943 demonstrates a favorable safety profile. The company also reports advancements in next-generation effector chemistry to improve the efficacy of approved antibody-drug conjugates. Vincerx plans to share more clinical data later this summer and at the 2024 European Hematology Association annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-77.82%
Tags
clinical trial
-
News
Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Rhea-AI Summary
Vincerx Pharma, Inc. to host a virtual investor event to review preliminary clinical data from its Phase 1 dose-escalation study of VIP236 and provide an update on pipeline progress. The event will feature presentations by key opinion leaders and the CEO, Ahmed Hamdy, MD. The company aims to address unmet medical needs in cancer treatment through innovative therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.61%
Tags
conferences clinical trial
-
News
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Rhea-AI Summary
Vincerx Pharma, Inc. reported financial results for Q4 and full year 2023, showcasing progress in their clinical programs including VIP236, VIP943, and enitociclib. VIP236, a first-in-class SMDC, and VIP943, a novel CD123-targeted ADC, are in Phase 1 trials, with encouraging preliminary data. Enitociclib, a CDK9 inhibitor, demonstrated promising results in Phase 1 combination studies. Vincerx's VersAptx platform showed significant advancements in bioconjugation technologies. The company's cash runway is expected to last into early Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
Rhea-AI Summary
Vincerx Pharma, Inc. announced the presentation of three posters at the AACR Annual Meeting 2024, including clinical data for VIP236, a small molecule-drug conjugate. The company will host a virtual investor event on April 8 to discuss preliminary Phase 1 data for VIP236. Vincerx aims to address unmet medical needs in cancer treatment through innovative therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.12%
Tags
conferences
-
News
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Rhea-AI Summary
Vincerx Pharma, a biopharmaceutical company (Nasdaq: VINC), announced promising clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for the treatment of relapsed/refractory lymphoma. The study reported 2 partial responses in 3 peripheral T-cell lymphoma patients and 1 partial response in 2 double-hit diffuse large B-cell lymphoma patients. Vincerx is also on track to report early clinical data from lead VersAptx™ platform compounds, VIP236 (early 2024) and VIP943 (mid 2024). Enitociclib is being hailed as a well-tolerated and effective partner for novel combinations, showing a high response rate and tolerability in patients with hard-to-treat types of non-Hodgkin’s lymphoma such as PTCL and DH-DLBCL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
Rhea-AI Summary
Vincerx Pharma, Inc. (Nasdaq: VINC) presented preclinical data for VIP943 and VIP924 at ASH 2023. VIP943, a CD123-targeted antibody-drug conjugate, showed on-target selectivity and activity in AML cell lines. VIP924, a CXCR5-targeted ADC, demonstrated superior efficacy and safety compared to commercially available B-cell targeted ADCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Vincerx Pharma, Inc. (Nasdaq: VINC) reported progress across all three clinical programs, including VIP943, the first antibody-drug conjugate (ADC) from the VersAptx Platform, and VIP236, a small molecule-drug conjugate (SMDC) for solid tumors. The company also provided a corporate update, highlighting the positive clinical results, FDA approval, and financial position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.99%
Tags
earnings
-
News
Vincerx Pharma To Present Three Posters at ASH 2023 in December
Rhea-AI Summary
Vincerx Pharma, Inc. will present three posters at the 65th American Society for Hematology Meeting. The posters will cover VIP943, a CD123-targeting antibody-drug conjugate (ADC) for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and B-cell acute lymphoblastic leukemia (B-cell ALL). VIP924, a CXCR5 ADC for the treatment of B-cell malignancies, will also be discussed. Additionally, preclinical data on enitociclib's activity in pediatric leukemia will be presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
conferences
-
News
Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023
Rhea-AI Summary
Vincerx Pharma to participate in Cantor Fitzgerald Global Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
conferences
News
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943
Rhea-AI Summary
Vincerx Pharma reports dosing of first patient in Phase 1 trial for VIP943
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
clinical trial
Stock VINC logo
Vincerx Pharma Inc

Nasdaq:VINC

VINC Rankings

#5142 Ranked by Market Cap
#3085 Ranked by Stock Gains
N/A Ranked by Dividends

VINC Stock Data

20.99M
17.61M
25%
40.77%
3.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Palo Alto

About VINC

vincerx is a clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.